{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:43:38Z","timestamp":1761155018079},"reference-count":26,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,7,11]],"date-time":"2006-07-11T00:00:00Z","timestamp":1152576000000},"content-version":"vor","delay-in-days":5031,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[1992,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Because B lymphocytes bearing the CD5 antigen have been involved in many B\u2010cell malignancies, we have investigated the presence of the CD5 B\u2010cell antigen on B and plasma cells in monoclonal gammopathy. Quantification of CD5 B cells was made in the peripheral blood of seven individuals with monoclonal gammopathy of undetermined significance (MGUS) and in that of 21 patients with multiple myeloma (MM). The bone marrow of ten patients with MM was also studied. Patients with progressive MM presented a significant reduction in both B and CD5 B lymphocytes (i.e., percentages and absolute numbers), when compared with individuals with MGUS and patients with stable MM. These latter individuals and patients did not differ from healthy donors. No CD5 B cells were found in the bone marrow of patients with MM. Moreover, no CD5 antigen could be detected on eight freshly established human myeloma cells lines including six totally dependent on Interleukin\u20106. However, it was weakly expressed on two standard myeloma cell lines not requiring exogenous interleukin\u20106 (i.e., RPMI 8226 and U 266). In conclusion, our data show mainly an overall reduction of the polyclonal CDS B lymphocytes similar to what is observed for the other polyclonal B lymphocytes in patients with active MM. Finally, the expression of the CDS antigen human myeloma cell lines is not constant. \u00a9 1992 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.2830410207","type":"journal-article","created":{"date-parts":[[2007,2,21]],"date-time":"2007-02-21T12:57:47Z","timestamp":1172062667000},"page":"102-106","source":"Crossref","is-referenced-by-count":4,"title":["CD5 B lymphocyte antigen in monoclonal gammopathy"],"prefix":"10.1002","volume":"41","author":[{"given":"R\u00c9Gis","family":"Bataille","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Duperray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue Guang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Brochier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,11]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"crossref","unstructured":"BroderS WaldmannTA:Characteristics of multiple myeloma as an immunodeficiency disease. In M. Potter (ed): Progress in Myeloma: Biology of Myeloma.1980 p151\u2013169.","DOI":"10.1016\/B978-0-444-00377-5.50012-1"},{"key":"e_1_2_1_3_2","first-page":"282","article-title":"Immunosuppression and infection in multiple myeloma","volume":"13","author":"Jacobson DR","year":"1986","journal-title":"Scmin Oncol"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.3109\/08916938909003048"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.1986.tb01502.x"},{"key":"e_1_2_1_6_2","first-page":"631","article-title":"Reactivity of Leu\u20101 and T101 monoclonal antibodies with B cell lymphomas (correlation with other immunological markers)","volume":"58","author":"Al Saati T","year":"1984","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.2.566.566"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI111540"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00916552"},{"key":"e_1_2_1_10_2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4049\/jimmunol.136.2.505","article-title":"Leu\u20101 + (CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: phenotype and functional studies","volume":"136","author":"Antin JH","year":"1986","journal-title":"J Immunol"},{"key":"e_1_2_1_11_2","first-page":"243","volume-title":"Recent advances in haematology","author":"Durie BGM","year":"1977"},{"key":"e_1_2_1_12_2","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood.V63.2.468.468","article-title":"Serum beta 2 micro globulin in myeloma: Optimal use for staging prognosis and treatment","volume":"63","author":"Bataille R","year":"1984","journal-title":"Blood"},{"key":"e_1_2_1_13_2","first-page":"2054","article-title":"Cell line derived from patient with myeloma","volume":"68","author":"Moore GE","year":"1968","journal-title":"NY Stat J Med"},{"key":"e_1_2_1_14_2","first-page":"477","article-title":"Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient","volume":"7","author":"Nilsson K","year":"1970","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/blood.V66.3.548.548","article-title":"Establishment of two new myeloma cell lines from bilateral pleural effusions: Evidence for sequential in vivo clonal change","volume":"66","author":"Durie BGM","year":"1985","journal-title":"Blood"},{"key":"e_1_2_1_16_2","first-page":"93","article-title":"Two new IgA1\u2010k plasma cell leukemia cell lines (JJN\u20101 and JJN\u20102) which proliferate in response to B cell stimulatory factor 2","volume":"15","author":"Jackson N","year":"1989","journal-title":"Clin Exp Immunol"},{"issue":"1","key":"e_1_2_1_17_2","first-page":"899","article-title":"IL\u20106 dependent human myeloma cell lines","volume":"74","author":"Klein B","year":"1989","journal-title":"Blood"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(81)90253-2"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(85)90274-1"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0769-2625(84)81192-7"},{"key":"e_1_2_1_21_2","first-page":"513","article-title":"CD5 positive B lymphocytes: A link between autoimmunity and B\u2010cell oncogenesiss","volume":"7","author":"Bataille R","year":"1988","journal-title":"Anticancer Res"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830370306"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4049\/jimmunol.139.1.24","article-title":"Multiple myeloma: an immunologic profile. IV. The EA rosette\u2010forming cell is a Leu\u20101 positive immunoregulatory B\u2010cell","volume":"139","author":"Mackenzie MR","year":"1987","journal-title":"J Immunol"},{"key":"e_1_2_1_24_2","first-page":"3224","article-title":"No expansion of the pre\u2010B and B\u2010cell compartments in the bone marrow of patients with multiple myeloma","volume":"51","author":"Duperray C","year":"1991","journal-title":"Cancer Res"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-2776(08)60663-X"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.145.11.3678"},{"key":"e_1_2_1_27_2","first-page":"775","article-title":"Establishment and characterization of a CDS positive immunosuppressive human myeloma cell line","volume":"4","author":"Scibienski RJ","year":"1990","journal-title":"Leukemia"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.2830410207","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.2830410207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T13:54:45Z","timestamp":1698069285000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.2830410207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,10]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992,10]]}},"alternative-id":["10.1002\/ajh.2830410207"],"URL":"https:\/\/doi.org\/10.1002\/ajh.2830410207","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,10]]}}}